RxDoctor Payments Data

Jason Flamm, MD

Internal Medicine · Sacramento, CANPI 1396823019

Payments from drug & device makers

$1,657,039in general payments, 2019–2025

Across 178 payments — averaging $9309.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$867K
  • Viiv Healthcare Company$740K
  • GSK$30K
  • Merck$20K
$1,085in research payments, 2019–2025

Across 9 payments — averaging $120.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$1K

What the payments were for

  • Food & beverage$28100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead103$866,734
Viiv Healthcare Company60$740,259
GSK7$30,108
Merck8$19,939

How this compares

$1,657,039 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$2,103
Medicare patients
12
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala200$2,042,325
TriumeqAbacavir/Dolutegravir/Lamivudi60$642,240
OdefseyEmtricitab/Rilpiviri/Tenof Ala68$573,052
TivicayDolutegravir Sodium36$249,353
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$112,889
DescovyEmtricitabine/Tenofov Alafenam12$75,398
EdurantRilpivirine Hcl12$38,340
OzempicSemaglutide41$30,340
EliquisApixaban12$25,660
Darunavir29$14,569
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df47$14,101
Spiriva RespimatTiotropium Bromide25$12,149
Humalog Kwikpen U-100Insulin Lispro14$8,040
PradaxaDabigatran Etexilate Mesylate26$6,992
AlvescoCiclesonide54$6,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$866,734$2,230,613225 claims
Viiv Healthcare CompanyTriumeq, Tivicay$740,259$891,59396 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →